 Immunoconjugates
"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 3 | 0 | 3 | | 2003 | 2 | 1 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 2 | 4 | | 2006 | 3 | 0 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 3 | 0 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 3 | 1 | 4 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 6 | 0 | 6 | | 2017 | 10 | 1 | 11 | | 2018 | 5 | 1 | 6 | | 2019 | 3 | 1 | 4 | | 2020 | 4 | 0 | 4 | | 2021 | 10 | 1 | 11 | | 2022 | 2 | 1 | 3 | | 2023 | 6 | 0 | 6 | | 2024 | 10 | 2 | 12 | | 2025 | 6 | 4 | 10 | | 2026 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Kamdar M, Bartlett NL. From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma. Blood. 2026 Jun 11; 147(24):2879-2894.
-
Chakravorty S, Zybina Y, Ahn E, Pradhan K, Yu N, Taylor M, Charati M, Wilson DC, Jeon AB, Blumenschein WM, Han JH. Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody-Drug Conjugate Payloads. Mol Cancer Ther. 2026 Jun 01; 25(6):976-991.
-
Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort. Mod Pathol. 2026 Jun; 39(6):101006.
-
Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA. Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma. Clin Cancer Res. 2026 Jan 06; 32(1):159-168.
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
-
Blomquist MR, Noviello TMR, Sereduk C, Grief D, Caruso FP, Sharma R, Garcia-Mansfield K, Pirrotte P, Kloss J, D'Angelo F, Marin BM, Porath K, Jain S, Rabichow B, Ensign SPF, Iavarone A, Paladino A, Sarkaria JN, Loftus JC, Ceccarelli M, Tran NL. Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression. J Transl Med. 2025 Oct 21; 23(1):1153.
-
Liang B, Tenney TB, Han L, Zhang X, Wang A, Barry-Holson KQ, Rosenzweig ER, Toland AMS, Diver EJ, Deutschman E, Method M, Sloss CM, Yang EJ, Charu V, Howitt BE. Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. Int J Gynecol Pathol. 2026 Jan 01; 45(1):9-17.
-
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N. A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2). Int J Gynecol Cancer. 2026 06; 36(6):102654.
-
Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, Gandhi L, Kudo T, Fujioka N, Kaplan J, Gorla S, Liu S, Wozniak M, Poondru S, Dillon R, Meng C, Patil T. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sep 09; 227:115603.
-
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Taniyama D, Patel M, Aber E, Contreras CF, Kaplan RN, Kiseljak-Vassiliades K, Wierman ME, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Del Rivero J, Roper N. Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma. Nat Commun. 2025 Jul 01; 16(1):5511.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|